MOTS-c: Benefits, Dosage & FDA Status
Mitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
FDA Status
Not FDA-approved — research peptide; multiple early-phase clinical trials
Typical Dose
5–10 mg, 2–3 times weekly (subcutaneous)
Evidence Grade
BLimited clinical + robust preclinical evidence
Half-Life
Hours (estimated)
Routes of Administration
subcutaneous
First Synthesized
2015
Clinics Indexed
22 providers have offered MOTS-c in our tracked directory.
Mechanism of Action
Encoded by the mitochondrial 12S rRNA; activates AMPK to improve glucose uptake, insulin sensitivity, and stress resistance.
Key Reported Benefits
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Benefits listed reflect commonly reported effects from clinical trials and practitioner use. Individual response varies. Evidence-grade B indicates limited clinical + robust preclinical evidence.
Reported Side Effects
- •Generally well-tolerated
- •Mild flushing
Contraindications
- ⚠Pregnancy
Regulatory & Safety Context
FDA status: Not FDA-approved — research peptide; multiple early-phase clinical trials
This page is for educational purposes only and does not constitute medical advice. Peptide use outside of an FDA-approved indication should be discussed with a licensed medical professional. Source quality, cold-chain storage, and injection hygiene all materially affect safety outcomes.
See state-by-state legality: US peptide legality by state →
References
Selected primary literature on MOTS-c. Full PubMed records linked. Additional citations are available on request.
Last reviewed: 2026-04-30
Related Peptides
Semaglutide
A+A GLP-1 receptor agonist and the gold standard for evidence-based weight loss peptide therapy. Demonstrated 14.9–16.9% mean body weight reduction in the landmark STEP trials.
Tirzepatide
A+A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
Liraglutide
A+The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.
Retatrutide
ATriple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.
Cagrilintide
AA once-weekly amylin analog that reduces appetite via the area postrema. Combined with semaglutide ('CagriSema') it has produced ~22% weight loss in trial data.
Epitalon
C+A synthetic tetrapeptide that reportedly upregulates telomerase activity. Russian longevity studies suggest mortality reductions but Western RCTs are absent.